Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Jason Coarse"'
Autor:
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili
Externí odkaz:
https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e
Autor:
Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies.Methods BE OPTIMAL (NCT0389520
Externí odkaz:
https://doaj.org/article/6b47e439da8445b083e973aca1ddd188
Autor:
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-
Externí odkaz:
https://doaj.org/article/8c6f7873019c4474b1623173fd071db0
Autor:
Laura C. Coates, Iain B. McInnes, Joseph F. Merola, Richard B. Warren, Arthur Kavanaugh, Alice B. Gottlieb, Laure Gossec, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Barbara Ink, Christopher T. Ritchlin
Publikováno v:
Arthritis & Rheumatology. 74:1959-1970
Autor:
Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, Laure Gossec
Publikováno v:
Rheumatology
Rheumatology, 2022, pp.keac353. ⟨10.1093/rheumatology/keac353⟩
Rheumatology, 2022, pp.keac353. ⟨10.1093/rheumatology/keac353⟩
Objectives Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients. Methods Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled tria
Autor:
Alice B. Gottlieb, A. Asahina, Laura C. Coates, B. Ink, P. J. Mease, Deepak Assudani, Jason Coarse, Laure Gossec, J. Eells, S. Hellot
Publikováno v:
Revue du Rhumatisme. 88:A26-A28
Autor:
Laura C, Coates, Iain B, McInnes, Joseph F, Merola, Richard B, Warren, Arthur, Kavanaugh, Alice B, Gottlieb, Laure, Gossec, Deepak, Assudani, Rajan, Bajracharya, Jason, Coarse, Barbara, Ink, Christopher T, Ritchlin
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)REFERENCES.
To assess the long-term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA).Adult patients with active PsA who completed the double- and dose-blind periods of the BE ACTIVE randomized controlled trial were eligible t
Autor:
William Tillett, Iain B McInnes, Dennis McGonagle, Deepak R Jadon, Barbara Ink, Deepak Assudani, Jason Coarse, Jason Eells, Laura C Coates
Publikováno v:
Rheumatology. 61
Background/Aims Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL17A, has demonstrated an acceptable safety profile with improvements in joint and skin outcomes to 3 years in patients with active psor
Autor:
Maxime Dougados, Atul Deodhar, Désirée van der Heijde, Jason Coarse, Dominique Baeten, Nadine Goldammer, M. Oortgiesen, Denis Poddubnyy, Mary Katherine Farmer, Alan Kivitz, Lianne S. Gensler, Xenofon Baraliakos
Publikováno v:
Annals of the Rheumatic Diseases, 79(5), 595-604. BMJ PUBLISHING GROUP
Annals of the rheumatic diseases, 79(5), 595-604. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 79(5), 595-604. BMJ Publishing Group
Annals of the Rheumatic Diseases
ObjectivesBimekizumab selectively neutralises both interleukin (IL)-17A and IL-17F. We report efficacy and safety in a phase IIb dose-ranging study in patients with active ankylosing spondylitis (AS).MethodsAdults with AS (fulfilling modified New Yor
Autor:
Joseph F. Merola, Akihiko Asahina, Christopher T. Ritchlin, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Jason Eells, Philip J. Mease
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB146